SCHEDULE: Trill AB and Jan Stahlberg Disclose 13.14% Stake in DiaMedica Therapeutics

Trill AB and its beneficial owner Jan Stahlberg have reported a 13.14% beneficial ownership stake in DiaMedica Therapeutics Inc., holding 6,764,465 common shares.

Summary

• Trill AB and Jan Stahlberg collectively beneficially own 6,764,465 common shares of DiaMedica Therapeutics Inc.
• This represents 13.14% of the company's common shares outstanding.
• The ownership percentage is calculated based on 42,883,465 shares outstanding as of May 9, 2025, plus an additional 8,606,426 shares expected from a private placement.
• The filing indicates a passive investment, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of beneficial ownership. The acquisition of a 13.14% stake by Trill AB and Jan Stahlberg could be viewed as a positive signal of investor confidence in DiaMedica Therapeutics Inc.

Positives

• A significant institutional and individual investor (Trill AB and Jan Stahlberg) has taken a substantial stake, potentially signaling confidence in the company.
• The investment is passive, suggesting stability rather than immediate activist intentions.

Future Outlook

NA

Management Comments

• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This filing indicates a significant investment in a biotechnology/pharmaceutical company (DiaMedica Therapeutics Inc.) by a Swedish entity and individual. Such investments can signal investor confidence in the company's pipeline or market position within the broader healthcare sector.

Comparison to Industry Standards

• A 13.14% stake is a substantial minority interest, often indicative of a strategic long-term investment rather than short-term trading.
• Compared to typical institutional holdings, this percentage is significant enough to warrant attention from other investors, though it falls short of a controlling interest.
• The certification of passive investment is standard for Schedule 13G filings by institutional investors not seeking to influence control.

Stakeholder Impact

• Shareholders: The disclosure of a significant new beneficial owner may influence investor perception and potentially share price.
• Company Management: Awareness of a large, passive shareholder.

Key Dates

Recommendation

The filing indicates a significant beneficial ownership stake by Trill AB and Jan Stahlberg, which could be interpreted as a vote of confidence. However, a Schedule 13G is a disclosure of ownership and does not provide financial performance or strategic updates that would warrant a strong buy or sell recommendation. It's a factual update on the shareholder base. Investors should hold and monitor future developments, including the impact of the private placement mentioned.

Keywords

DiaMedica Therapeutics, Trill AB, Jan Stahlberg, Schedule 13G, beneficial ownership, equity stake, institutional investment, biotechnology, pharmaceutical